Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

• Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options
• Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-'749 after more than 3,400 subcutaneous injections in study participants to date
• As a leader in neuroscience, Teva is committed to researching and developing long-acting treatment options that help address unmet needs for individuals living with schizophrenia

PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of real-world clinical outcomes, treatment patterns and healthcare resource utilization (HCRU) data evaluating UZEDY® (risperidone), an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, versus second-generation daily oral options. In the studies, patients receiving UZEDY had lower rates of and longer time to relapse as well as better treatment adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits, shorter hospital length of stay and lower all-cause HCRU. Additionally, Phase 3 SOLARIS data show no incidence of post-injection delirium/sedation syndrome (PDSS) to date in participants taking TEV-'749, a once-monthly, long-acting injectable (LAI) subcutaneous formulation of olanzapine. The systemic safety profile was consistent with approved olanzapine options. The data were presented at the 2025 Psych Congress Elevate Annual Meeting, taking place from May 28-31, 2025, in Las Vegas, Nevada.

“People living with schizophrenia and their caregivers face a number of significant daily challenges, including barriers to optimal treatment. For those who struggle adhering to a daily oral regimen, UZEDY may be an appropriate option to help prevent relapse, reduce hospital visits and lower overall costs to the healthcare system,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “With TEV-'749, our latest data demonstrate its potential to fill a critical gap in the current schizophrenia treatment landscape as a long-acting formulation of olanzapine that may effectively address the risk of PDSS.”

To view full press release, please visit: https://www.globenewswire.com/news-release/2025/05/31/3091373/0/en/Teva-Presents-Latest-Schizophrenia-Portfolio-Data-Including-Real-World-Outcomes-with-UZEDY-risperidone-Showing-Lower-Rates-of-and-Longer-Time-to-Relapse-Compared-to-Oral-Treatment-.html